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 Curcumin, a polyphenolic compound, derived from the rhizomes of 
Curcuma longa L. Curcumin shows potential pharmacological action 
against numerous disorders, including cancer, neurodegenerative, and 
infection diseases. Curcumin-based molecular imaging agents could be 
useful for early detection of Alzheimer's Disease and tumor and monitor the 
progress of therapy. Radiolabeled curcumin and its derivatives become 
promising compounds as imaging agents. In this review, radiolabeled 
curcumin bearing radionuclides including Fluorine-18, Technetium-99m, 
Iodine-125, and Gallium-68 are reviewed as an effort to develop curcumin-
based probes not only for β amyloid imaging but also for tumor imaging. 
 
I. Introduction 
The accumulation of β-amyloid (Aβ) 
aggregates and neurofibrillary tangles in human 
brain are still considered some of the key features for 
neurodegenerative disorder namely Alzheimer’s 
disease (AD) (Uzuegbunam, Librizzi and Yousefi, 
2020). Histological examination of brain sample is 
still required to assign a definitive diagnosis of AD 
(Takizawa et al., 2015). However, using 
cerebrospinal fluid (CSF) biomarkers and positron 
emission tomography (PET) agents of patient which 
combined with several new clinical criteria, AD can 
be early diagnosed and monitored (Budson and 
Solomon, 2012; Jack et al., 2018). PET imaging is a 
non-invasive imaging technique that allows 
identifying the patients who are at risk of developing 
AD, and also to monitor disease progression or both 
(Steven T DeKosky and Marek, 2003; Reiman and 
Jagust, 2012). Hence, PET imaging agent may serve 
as an attractive diagnostic tool to monitor disease 
progression and the interaction of ligands with their 
targets (Bailey et al., 2005). Aβ is the most studied 
and first target for the neuroimaging of AD (Filippi 
et al., 2018), hence it is no surprise that there are 
already selective PET radiotracers for its imaging. 
Food and Drug Administration (FDA) approved 
Amyvid ([18F]florbetapir), Neuraceq 
([18F]florbetaben), and Vizamyl ([18F]flutemetamol) 
(Figure 1) as PET radiotracer for AD. 
Recently, several studies reported that 
curcumin showed high affinity toward Aβ plaques. 
Curcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-
1,6-heptadiene-3,5-dione, is a yellow-polyphenol 
pigment isolated from the rhizomes of Curcuma 
longa L and commonly known as turmeric 
(Hewlings and Kalman, 2017). The structure of 
curcumin shown in Figure 1. Curcumin has a wide 
spectrum of pharmacological actions and it has been 
reported to have anti-inflammatory (Zhu et al., 
2014), anti-microbial (Chen et al., 2016), anti-
oxidant (Banez et al., 2020), anti-carcinogenic 
(Perrone et al., 2015; Zhao et al., 2017; Walker and 
Mittal, 2020) activities. Because of its distinctive 
uptake in normal and cancer cells (Kunwar et al., 
2008; Heger et al., 2014), radiolabeled curcumin is 
one of attractive agents for tumor targeting 
radiopharmaceuticals. The present work introduces 
radiolabeled curcumin and its derivatives focusing 
on radiotracers for cancer and Aβ imaging. 
II. Research Method 
This review was designed to represent the 
in-depth potential of radiolabeled curcumin and its 
derivatives as β amyloid and tumor imaging agents. 
Literature searching in electronic databases, such as 
PubMed, Google Scholar, Web of Science, PubMed, 
and Scopus, were carried out using the keywords 
“curcumin”, “β amyloid“, “tumor”, “SPECT”, 
“PET”, “curcuminoid”, “99mTc-curcumin”, “125I-
curcumin”, “67/68Ga-curcumin”, “18F-curcumin”, 
and “Curcuma longa L” as the keywords for primary 
searches and secondary search items were used as 
follows: “imaging agent”, “natural product”, “Aβ 
imaging”, “cancer imaging”, and “radiolabel”. 
 
III. Results and Discussion 
III.1 Radiolabeled Curcumin 
Molecular imaging is a type of non-
invasively medical imaging that allows to visualize, 
Effendi: Radiolabeled curcumin as β amyloid imaging and tumor targeting imaging agents 
 
6 | Jurnal Fitofarmaka Indonesia, vol. 8 no. 3, 2021 
 
characterize, and measure the biological processes at 
molecular and cellular levels (Mankoff, 2007). 
Nuclear medicine is a revolutionized invention in 
diagnostic imaging using radiopharmaceuticals 
because it can be utilized to diagnose diseases 
noninvasively and facilitate monitoring disease 
progression or response to treatment of therapy 
repeatedly. Using single photon-emission computed 
tomography (SPECT) and PET imaging the 
diagnosis and progress of therapy the molecular 
target can be assessed (Fass, 2008; Cunha et al., 
2014). SPECT has some merits such as low cost and 
more assessable than PET, even though PET has 
better sensitivity and resolution (Galbán et al., 
2010). Due to its pharmacological and biological 
actions, radiolabeled curcumin and their derivatives 
could be potential biomarkers for imaging of 
Alzheimer’s disease and cancer by means of nuclear 
medicine imaging techniques which could be useful 
for early detection of them and contribute to 
personalized medicine. 
As promising compound, radiolabeled 
curcumin and its derivatives have been developed 
and evaluated their feasibilities as imaging agents. 
Radiogallium (Orteca et al., 2019) and 
radioiodinated (Kumar, Subramanian and Samuel, 
2016) curcumin have been reported as cancer 
imaging agents. Other studies showed the 99mTc 
(Sagnou et al., 2011) and 18F (Kim et al., 2019) 
labeled curcumin have been used as β-amyloid 
plaques imaging agents. 
III.1.1 18F-curcumin 
Fluorine-18 (18F) is one of PET 
radionuclides that routinely utilized in radiolabeling 
of biomolecules with half-life of 109.8 min 
(Alauddin, 2012). High spatial resolution and high 
sensitivity are two vaporable properties of PET 
imaging agent. However, high cost in preparation 
limited its use. Radiofluorinated-curcumin as 






Ryu et al. synthesized eight curcumin and 
its derivatives and evaluated their binding affinity 
for Aβ plaques. The binding affinity (Ki) of FPC to 
Aβ aggregates was 0.07 nM. The accumulation of 
[18F]FPC (Figure 2) in the mice brine 2 min and 30 
min after injection was 0.5 %ID/g and 
0.11 %ID/gram respectively. This probe was 
metabolically stable in brain. Therefore, [18F]FPC 
exhibited potential probes as Aβ imaging agent (Ryu 
et al., 2006). However, [18F]FPC has poor brain 
permeability may be caused by its fast metabolism 
in liver and intestine. 
2. [18F]1-(4-[18F]Fluoroethyl)-7-(4′-
methyl)curcumin ([18F]FEC) 
Lee and group synthesized five curcumin 
derivatives and their binding affinities for Aβ (1-40) 
aggregates have been evaluated. The binding 
affinity (Ki) of FEC was 2.12 nM. Subsequently, 
accumulation of radiofluorinated 1-(4-fluoroethyl)-
7-(4′-methyl)curcumin (Figure 2) in normal mice 
brain was 1.44 and 0.45 %ID/gram at 2 and 30 min 
post-injection, respectively. This result indicated 
that [18F]FEC has better brain permeability than 
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In 2019, Kim at al. reported four 
difluoroboron-curcumin derivatives and selected 
one of them to be evaluated its feasibility as Aβ 
imaging agent, namely 4′-dimethylamino-4″-(2-(2-
fluoroethoxy)ethoxy) curcuminoid. In that study, 
[18F]DFEC as seen in Figure 2 was selected for 
further in vitro and in vivo evaluations based on 
binding affinity (Kd) value for Aβ(1-40) aggregates 
(19.66 nM) and feasibility for radiofluorinated 
labeling. [18F]DFEC exhibited high in vitro stability. 
In addition, low accumulation of [18F]DFEC in 
femur indicated that this probe was in vivo stable. 
Low initial brain uptake in biodistribution result at 2 
min post-injection (0.49 %ID/gram) and delay 
wash-out from the brine (1.19 %ID/gram at 60 min 
post-injection) has been reported (Kim et al., 2019). 
4. [18F]F-labeled dibenzylideneacetone 
derivatives ([18F]FHC) 
Using structure activity relationship (SAR) 
Cui et al. synthesized and evaluated two 
radiofluorinated curcumin derivatives which have 
high affinity for Aβ aggregates. There are (1E,4E)-
1-(4-(dimethylamino)phenyl)-5-(4-(2-(2-(2-
fluoroethoxy)-ethoxy)ethoxy)phenyl)penta-1,4-
dien-3-one (DPFP) and (1E,4E)-1-(4-(2-(2-(2-
fluoroethoxy)ethoxy)ethoxy)phenyl)-5-(4-
(methylamino)phenyl)penta-1,4-dien-3-one 
(FPMP) with Ki value were 6.9 ± 1.4 nM and 8.6 ± 
1.3 nM, respectively. Radiofluorinated compounds, 
[18F]DPFP and [18F]FPMP (Figure 2), have log D 
value were 2.97 and 3.08, respectively. Both 
radiofluorinated compounds has initial brain uptake 
at 2 min post-injection about 4.13 ± 0.41 and 5.15 ± 
0.17 %ID/gram. At 30 min post-administration the 
probes retained about 1.04 and 1.35 %ID/gram in 
mice brine (Cui et al., 2011). 
5. [18F]F-labeled hydrazinocurcumin derivative 
([18F]FHC) 
In 2015, Shin at al. reported their studies in 
preparation of radiofluorinated hydrazinocurcumin 
derivatives (Figure 3). This probe was accumulated 
in human umbilical vascular endothelial cells and rat 
C6 glioma cells. Biodistribution data exhibited that 
[18F]FHC-2 accumulated in tumor of C6 glioma-
xenograft mice (3.20 ± 0.35% ID/gram vs 0.98 ± 
0.31% ID per g for [18F]FHC-1) at 30 min post-
injection. The accumulation of [18F]FHC-2 in C6 
glioma-tumor model mice could be visualized 
clearly using PET camera, which cannot be shown 






Figure 3. Dynamic small animal PET images of (A) [18F]FHC-1 and (B) [18F]FHC-2 in glioma tumor-bearing 
mice modified from Shin et al. (Shin et al., 2015), reproduced by permission of The Royal Society of Chemistry
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III.1.2 99mTc-curcumin 
Technetium-99m (99mTc) is generated by 
transportable 99Mo-99mTc generator, readily 
available, and inexpensive. 99mTc is an attractive 
radionuclide for SPECT imaging due to its favorable 
physical and chemical properties, such as a low γ-
rays emission (140 keV, 89% abundance) and a 
moderate half-life (6 h) which is sufficient for 
preparation of 99mTc-based radiopharmaceuticals 
(International Atomic Energy Agency (IAEA), 
2009; Boschi, Uccelli and Martini, 2019). 99mTc-
labeled curcumin as Aβ imaging agents have been 
reported, some of them detailed as below:  
1. fac-[99mTc(CO)3(curcu)-(imi)] and fac-
[99mTc(CO)3(curcu)-(isc)] 
Sagnou et al. reported two novels 99mTc-
labeled curcumin derivatives, fac-
99mTc(CO)3(curcu)-(imi) and fac-
99mTc(CO)3(curcu)-(isc) (Figure 4) using ″2+1″ 
ligand system. This group synthesized and 
characterized ″2+1″ complexes of the [M(CO)3] (M 
= Re and 99mTc) core with curcumin as bidentate OO 
ligands and imidazole (imi) and 
isocyanocyclohexane (isc) as monodentate ligands. 
In vitro binding affinity of non-radioactive rhenium 
labeled curcumin complexes was performed using 
Alzheimer′s disease brain slices to assess their 
feasibilities as Aβ imaging agents. The fluorescence 
microscope image visualized clearly the plaques of 
human AD brine slices, despite the significant 
difference in their fluorescence intensity was found 
(Sagnou et al., 2011). 
2. fac-[99mTc/Re(cur)-(PPh3)2(CO)2] and fac-
[99mTc/Re(cur)-(PPh3)(CO)3] 
In 2013, Triantis et al. reported the 
preparation the non-radiolabeled (Rhenium 
complexes) and radiolabeled (99mTc complexes) of 
curcumin derivatives, fac-[99mTc/Re(cur)-
(PPh3)2(CO)2] and fac-[99mTc/Re(cur)-(PPh3)(CO)3] 
(Figure 4). Using ″2+1″ ligand system, they 
synthesized both curcumin-based probes, wherein 
phosphine utilized as the monodentate ligand and 
complexes of the fac-[M(CO)3] (M = Re and 99mTc) 
core with curcumin as bidentate OO ligand. In vitro 
staining of human post-mortem AD brain sections 
with rhenium-curcumin complexes which visualized 
under the fluorescence microscope exhibited both 













Figure 4. The chemical structure of fac-[99mTc/Re(CO)3(curcu)-(imi)], fac-[99mTc/Re(CO)3(curcu)-(isc)], fac-
[99mTc/Re(cur)-(PPh3)2(CO)2], and fac-[99mTc/Re(cur)-( PPh3)(CO)3] 
III.1.3 125I-curcumin 
Radionuclides of iodine have been 
widely used in various fields of medicinal and 
biological sciences. These radionuclides insert into 
bioactive molecules to visualize the molecular target 
non-invasively and to diagnose the particular disease 
(Effendi et al., 2019). There are some types of iodine 
radionuclides with different type of ray emission, 
such as iodine-123 (SPECT), iodine-124 (PET), 
iodine-125 (preclinical research and Auger therapy), 
iodine-131 (β-therapy) (Dubost et al., 2020). 
Identical chemical properties of iodine radionuclides 
allow the in vitro and in vivo information from one 
radioiodine nuclide bearing bioactive compound 
serve as basic data for further work (Effendi et al., 
2018). Radioiodine-labeled curcumin probes have 
been reported, some of them described as follow: 
1. 125I-curcumin 
In 2013, Kumar et al. reported their studies 
in preparation of radioiodinated curcumin as tumor-
targeting probes. Using iodogen method, Iodine-125 
was inserted into curcumin to obtain 125I-curcumin 
(Figure 5) with radiochemical yield more than 75% 
and high purity (>95). Accumulation of 125I-
curcumin in EL4 murine lymphoma cells reached 
6.8% dose/500,000 cells. The tumor uptake of 125I-
curcumin in lymphoma-tumor model mice reached 
3.3% ID/gram at 3 h post-injection. The 
biodistribution data exhibited that 125I-curcumin was 
washed-out slowly from blood and other non-
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Figure 5. The chemical structure of [125I]curcumin, [125I]APIP, and [125I]IPMP 
2. Radioiodinated dibenzylideneacetone 
derivatives 
Cui et al. synthesized two radioiodinated 
dibenzylideneacetone derivatives for SPECT Aβ 
imaging, radioiodinated (1E,4E)-1-(4-
aminophenyl)-5-(4-iodophenyl)penta-1,4-dien-3-
one ([125I]APIP) and (1E,4E)-1-(4-iodophenyl)-5-
(4-(methylamino)phenyl)penta-1,4-dien-3-one 
([125I]IPMP) (Figure 5) (Cui et al., 2011). In vitro 
binding affinity (Ki) value of APIP and IPMP were 
7.0 ± 2.2 nM and 2.8 ± 0.5 nM, respectively. 
Meanwhile, Log D values of [125I]APIP and 
[125I]IPMP are 3.26 ± 0.05 and 3.55 ± 0.02, 
respectively. Accumulation of [125I]APIP in mice 
brine at 2 post-injection were 4.56 ± 0.42 and 
decreased to 1.36 ± 0.19 %ID/gram at 30 min post-
injection. While brain uptake of [125I]IPMP after 2 
min reached 4.68 ± 0.25 %ID/gram and after 30 min 
reduced to 1.38 ± 0.23 %ID/gram (Cui et al., 2011). 
III.1.4 68Ga-curcumin 
The radionuclide 68Ga has a great 
potential property for clinical PET and could be an 
attractive alternative to 18F which require an on-site 
cyclotron in production. 68Ga is a generator-
produced radionuclide with a half-life of 68 min. In 
principle, the long half-life of the parent nuclide 
67Ge (270.8 days) provides a generator with a long 
life span (Martiniova et al., 2016). Radionuclide Ga-
67 usually was used in initial evaluation of 
radiogallium complexes due to it is an easy-to-
handle radioisotope with a longer half-life (3.3 days) 
than 68Ga. The following is detailed some curcumin-
based radiogallium probes as tumor-targeting and 
Aβ imaging agents. 
1. [68Ga] labeled curcumin and curcuminoid 
complexes ([68Ga](CUR)2+, [68Ga](bDHC)2+, 
and [68Ga](DAC)2+)  
Asti and groups synthesized and 
characterized curcumin and curcuminoid-based 
radiogallium complexes, their chemical structures 
were displayed in Figure 6. Subsequently, they 
evaluated their binding affinity for Aβ and uptake in 
A549 lung cancer cells. [68Ga](CUR)2+, 
[68Ga](bDHC)2+, and [68Ga](DAC)2+ were 
synthesized in high radiochemical yield and purity 
and in vitro stable in saline and human serum. All of 
probes were accumulated in A549 lung cancer cells. 
Meanwhile, [68Ga](CUR)2+and [68Ga](DAC)2+ 
showed high binding affinity for synthetic Aβ fibrils 
(Asti et al., 2014). 
In another year, this group (Rubagotti et al., 
2016) continued the evaluation of these radiogallium 
probes and explored their feasibility as Aβ imaging 
agents. They reported that [68Ga](CUR)2+ and 
[68Ga](DAC)2+ complexes have high binding affinity 
for synthesized Aβ fibrils and medium affinity has 
been shown by [68Ga](bDHC)2+ (in vitro study). On 
the other hand, in in vivo study using post-mortem 
brain cryosections of male Tg2576 mice, all of 
gallium complexes could not visualize amyloid 
plaques. Low in vivo stability of complexes and a 
hampered passage across the blood-brain barrier 













Figure 6. The chemical structure of [68Ga](CUR)2+, [68Ga](bDHC)2+, [68Ga](DAC)2+, and [68Ga]DOTA-C21 
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2. [68Ga]DOTA labeled curcumin ([68Ga]DOTA-
C21) 
Orteca et al. explored curcuminoid-based 
radiogallium complexes as colon-rectal carcinoma 
imaging. [68Ga]DOTA-C21 uptake in HT29 
colorectal cancer and K562 lymphoma cells was 
comparable to normal human lymphocytes. 
Biodistribution result exhibited that [68Ga]DOTA-
C21 was accumulated in HT29 tumor-xenograft 
mice at 1 h post-administration (2.27 ± 
0.85 %ID/gram increased to 3.57 ± 0.3 %ID/gram at 
1.5 h post-injection. [68Ga]DOTA-C21 retained for 
long enough in blood and some others non-targeted 
tissues such as small intestine, kidney, and lung 
(Orteca et al., 2019). 
IV. Conclusions 
In this review, we introduced a variety of 
radiolabeled curcumin as Aβ imaging or tumor-
targeting imaging agents. Curcumin has a wide 
spectrum of biological and pharmacological actions. 
Anti-inflammatory, anti-microbial, anti-oxidant, 
and anti-carcinogenic activities of curcumin have 
been studied. A sufficient binding affinity of 
curcumin for β amyloid as one of biomarker for 
Alzheimer's Disease encourage curcumin become a 
promising compound for Aβ imaging and tumor 
targeting imaging. Nuclear medicine imaging as 
non-invasively technique to visualize the molecular 
target in order to get early detection of disease and 
monitor the progress of treatment has attractive 
attention oncologist and researchers. Some 
promising curcumin-bearing radionuclide 
derivatives have been developed in recent years as 
introduced some of them in this review. However, 
structure modification of them is still needed to 
guarantee an appropriate imaging agent not only for 
Aβ imaging but also for tumor imaging. Hopefully, 
novel curcumin-based imaging agents with 
promising properties could be developed in the near 
future. 
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